![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Diabetomics’s Saliva-Based COVID-19 Test Gets FDA Emergency Use Authorization
Diabetomics’s Saliva-Based COVID-19 Test Gets FDA Emergency Use Authorization
The FDA has granted Diabetomics an Emergency Use Authorization for its COVID-19 antibody test, CovAb.
The test assesses saliva samples, delivers results within 15 minutes and detects all three COVID-19 antibody classes—IgA, IgG and IgM—that are present at different stages of infection.
The highly accurate test has 97.6 percent sensitivity and 98.8 percent specificity, according to the Hillsboro, Ore.-based company.
Upcoming Events
-
21Oct